RNA STOCK ANALYSIS

Atrium Therapeutics, Inc. Common Stock — price, returns and risk statistics

RNAAtrium Therapeutics, Inc. Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Last Close

13.65 $

Jul 2, 26

Market Cap

233.5 M $

Q1 2026 (TTM)

52-Week Range

Total Return

%-7.5

Trailing 1-year performance

Volatility

%46.8

Price fluctuation measure

Sharpe Ratio

-1.10

Risk/Return ratio

Sortino Ratio

-1.06

Downside risk/return

Distance to Peak

%-17.5

Difference from 52-week peak

Maximum Drawdown

-%30.2

Deepest 1-year decline

Seasonality Chart

Current Period 2026

3/3 positive months

Periodic Returns

+11.4%

+1.6%

—

YTD

—

Returns are computed from split-adjusted closes; dividends are not included.

YTD Return — Stock vs Asset Classes

Year-to-date

Stock and gold/silver returns are in USD (metals converted into the stock's currency). The S&P 500 index is measured in its own currency.

Monthly Avg Positive/Negative Close

Positive Count

Negative Count

Average Positive %

Average Negative %

Frequently Asked Questions

What is the current Atrium Therapeutics, Inc. Common Stock (RNA) stock price?

RNA last closed at 13.65 $ (Jul 2, 26). Price data is refreshed after every trading day.

What is the market capitalization of Atrium Therapeutics, Inc. Common Stock?

Atrium Therapeutics, Inc. Common Stock (RNA) has a market capitalization of approximately 233.5 M $ as of the latest reported period.

Who are the main competitors of RNA?

Key peers of Atrium Therapeutics, Inc. Common Stock include Mesoblast Ltd, RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S., TELIX Pharmaceuticals Ltd. A detailed metric comparison is available on the Peers tab.

Go deeper on RNA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.